Global Intellectual Property Specialists
Strategic global thinking for the pharmaceutical and biopharmaceutical industries
We use our global experience to support life sciences clients from early R&D to commercial launch, and beyond.
Explore our BioBlast®
View our interactive biosimilar news updates, collating tailored reports by brand, INN, originator/biosimilar applicant, litigation, region, or date.
Our lawyers and attorneys have science backgrounds, were trained at top tier firms, and most have experience in-house at multinational giants.
Award-winning IP services
Ranked internationally and domestically, our pharmaceutical, biopharmaceutical and life sciences focussed lawyers and attorneys are recognised as being among the best IP practitioners in the world.
Pearce IP is a boutique firm offering intellectual property specialist lawyers, patent attorneys and trade mark attorneys, to the pharmaceutical, biopharmaceutical and life sciences industries.
We coordinate and execute local and multi-jurisdictional IP litigation strategies, provide IP/legal support for regional and global business development activities and licensing deals, and prosecute patent and trade mark applications around the world.
IP SPECIALISTS LAWYERS – PATENT ATTORNEYS – TRADE MARK ATTORNEYS
PEARCE IP BLOG
Read our latest updates & insights
Schlam dunk – Federal Court makes Norwich Pharmacal orders against third party new employer
Following a trend of cases being filed by employers against ex-employees in the Federal Court for breach of confidence...
Pearce IP joins GBMA: Working with GBMA to enable access to affordable medicines
Pearce IP, an award-winning Australian boutique Intellectual Property firm, specialising in the pharma, biopharma and...
BioBlast w/e 26 May 23
26 MAY 2023 | EU | Celltrion files MAA with EMA for biosimilar to Janssen’s Stelara® (ustekinumab) Korea...
Product specific reports based on extracts from our BioBlast® database
aflibercept | Eylea® | Regeneron
bevacizumab | Avastin® | Roche/Genentech
cetuximab | Erbitux® | BMS/Merck
darbepoetin | Aranesp® | Amgen
denosumab | Prolia®/Xgeva® | Amgen
dupilumab | Dupixent® | Sanofi-Aventis
eculizumab | Soliris® | Alexion
filgrastim (GCSF) | Neupogen® | Amgen
golimumab | Simponi® | Janssen
guselkumab | Tremfya® | Janssen
infliximab | Remicade® | Johnson & Johnson
ixekizumab | Taltz® | Eli Lilly
natalizumab | Tysabri® | Biogen/Elan
omalizumab | Xolair® | Genentech / Novartis
pegfilgrastim | Neulasta® | Amgen
pembrolizumab | Keytruda® | Merck
ranibizumab | Lucentis® | Genentech
regdanvimab | Regkirona® | Celltrion
risankizumab | Skyrizi® | AbbVie
rituximab | Rituxan®/MabThera® | Genentech/Biogen
secukinumab | Cosentyx® | Novartis
tocilizumab | Actemra® | Roche
trastuzumab | Herceptin® | Roche/Genentech
ustekinumab | Stelara® | Johnson & Johnson/Janssen
By 2027, be the premier life sciences IP practice in Australia.
AWARD WINNING IP SPECIALISTS LAWYERS - PATENT ATTORNEYS - TRADE MARK ATTORNEYS